<DOC>
	<DOCNO>NCT01822678</DOCNO>
	<brief_summary>Multicentre , double-blind , randomise , parallel-group , placebo-controlled dose-titration study ; depend clinical efficacy , up-titration dosage 3 6 day start treatment ; maintenance individual maximum dose rest total 3-week treatment period ; subsequently , down-titration ( accord dose step time interval up-titration ) administration establish anti-manic therapy tapering-off period ( patient discontinue treatment ) entry recurrence prevention study ( Protocol PRA+SCO/BIA-2093-205 ; report separate cover ) option patient respond study treatment</brief_summary>
	<brief_title>Efficacy Safety Eslicarbazepine Acetate ( BIA 2-093 ) Acute Manic Episodes Associated With Bipolar I Disorder</brief_title>
	<detailed_description>Objectives : The primary objective evaluate dose-dependent efficacy 2 dose-titration regimen Eslicarbazepine Acetate ( ESL ) compare placebo therapy patient acute mania . The secondary objective evaluate safety tolerability 2 dose-titration regimen Eslicarbazepine Acetate comparison placebo .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>age ≥18 year ; document diagnosis bipolar I disorder accord Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criterion ( i.e. , 296.0 , 296.4 296.6 ) [ 8 ] ; currently display acute manic ( include mix ) episode accord DSMIV criterion ; Young Mania Rating Scale ( YMRS ) total score ≥20 ; symptom current manic episode start within 2 week prior randomisation ( V2 , Day 1 ) ; able undergo standard evaluation , include clinical interview , rating laboratory study ; sign informed consent form ; postmenopausal otherwise incapable become pregnant reason surgery tubal ligation ; woman childbearing potential present serum pregnancy test consistent nongravid state use doublebarrier contraception poststudy visit ( PSV ) . history schizophrenia schizoaffective disorder , psychotic feature rapid cycling ; currently treat carbamazepine oxcarbazepine ; history unresponsiveness , intolerance hypersensitivity relate compound ( carbamazepine , oxcarbazepine licarbazepine ) ; use depotneuroleptics current manic episode ; abuse stimulate drug use systemic sympathicomimetic drug within previous 2 week ; electroconvulsive therapy within previous 3 month ; history dependence chronic abuse alcohol , drug medication within last year ; judge clinically risk harm self others ; second thirddegree atrioventricular blockade correct pacemaker ; relevant electrocardiogram ( ECG ) laboratory abnormality ; calculate creatinine clearance &lt; 30 mL/min [ men : ( 140age ) x weight / serum creatinine x 72 ; woman : ( 0.85 ) ( 140age ) x weight / serum creatinine x 72 . Age year , weight kg , serum creatinine mg/dL ] ; pregnant nursing ; participate another drug clinical trial within last 2 month randomisation visit ; ensure capability perform trial comply study protocol ( e.g. , mental retardation severe inability communicate ) ; uncontrolled clinically relevant disorder ; previous treatment Eslicarbazepine Acetate ; history presence bone marrow impairment depression ( introduce protocol amendment No . 1 ) ; history presence acute intermittent porphyria ( introduce protocol amendment No . 1 ) . Patients receive treatment bipolar disorder central nervous system disorder randomisation exclude randomisation . If patient previously use medication follow restriction take account : Patients treat bipolar disorder preventive medication ( carbamazepine oxcarbazepine see exclusion criterion ) , antidepressant , antipsychotic , anxiolytic , antiparkinsonian , and/or potentially centrally act drug washedout least 2 day prior randomisation ( V2 , Day 1 ) . Patients treat lithium valproate could randomise plasma level &lt; 0.5 mmol/L &lt; 50 mg/L , respectively .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>